Meet the Elementa Labs 2025 Winter Cohort
By Dov Shamir, PhD Head of Elementa Labs and Assistant Director, Entrepreneurship at MSIP Elementa Labs is pleased to announce its fifth cohort! Mount Sinai Innovation Partners (MSIP) recently shared how Elementa Labs provides an open and collaborative incubator with companies that have …
Elementa Labs: Startup Incubator Retrospective and Trends for 2025
By Dov Shamir, PhD Head of Elementa Labs and Assistant Director, Entrepreneurship at MSIP As we begin 2025, Mount Sinai Innovation Partners (MSIP) Elementa Labs is celebrating its four-year anniversary. In the coming weeks, MSIP will be announcing its fifth cohort and …
MSIP Recognizes Researchers at Annual Innovation Awards Ceremony
The annual Mount Sinai Innovation Awards Ceremony took place on October 28. A hybrid event, the ceremony honored researchers from across the System for various achievements and included two awards presented by MSIP: Inventor of the Year and Transaction of the Year. …
IPGaia and the Icahn School of Medicine at Mount Sinai Announce Comprehensive Collaborative Research and Development Agreement
IPGaia Inc. (“IPG”) and the Icahn School of Medicine at Mount Sinai (“Icahn Mount Sinai”) have entered into a Comprehensive Collaborative Research and Development Agreement (“this agreement”) dated August 7th, 2024. This agreement establishes a formal framework for the incorporation of promising …
MSIP’s Entrepreneurship Updates: Pitch Challenge Winners, Upcoming Program Dates, and More
Discover the winners of the Mount Sinai Pitch Challenge and learn about MSIP’s Entrepreneurship Program, including how to apply for the upcoming cycle! The MSIP Entrepreneurship Program helps to equip innovators with the skills to identify unmet healthcare needs and develop innovative …
New York State Biodefense Commercialization Fund at a Glance
Take a look at the exciting updates from the New York State (NYS) Biodefense Commercialization Fund and discover how MSIP is aiding the growth of program participants and healthcare innovations. The New York State (NYS) Biodefense Commercialization Fund was established in 2021, …
HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms
Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the closing of its license agreements with the …
MSIP Recognizes Researchers and i3 Funding Awardees at Annual Innovation Awards Ceremony
The annual Mount Sinai Innovation Awards Ceremony took place on November 6. A hybrid event, the ceremony honored researchers from across the System for various achievements and included awards presented by MSIP: Inventor of the Year and Transaction of the Year. MSIP …
Nina Bhardwaj, MD, Discusses her Cancer Vaccine Research with MSIP
Meet Nina Bhardwaj, MD, PhD, Professor of Medicine (Hematology and Medical Oncology) and Urology, and Medical Director of the Vaccine and Cell Therapy Laboratory (VCTL) at the Icahn School of Medicine at Mount Sinai. Dr. Bhardwaj and her team are conducting groundbreaking …
Icahn School of Medicine at Mount Sinai Licenses Next-Generation Diagnostic Test Epigenetic /AI Platform to GNOMX Corp.
The Icahn School of Medicine at Mount Sinai has agreed to an exclusive license option with GNOMX Corp. (GNOMX) for epigenetic diagnostic and prognostic technology for infectious diseases. This groundbreaking patent-pending technology was developed by collaborating researchers at Icahn Mount Sinai, Princeton …